In Vivo Activities of Amoxicillin and Amoxicillin-Clavulanate against *Streptococcus pneumoniae*: Application to Breakpoint Determinations

D. ANDES* AND W. A. CRAIG

University of Wisconsin, Madison, Wisconsin

Received 20 January 1998/Returned for modification 25 March 1998/Accepted 10 June 1998

Infections caused by *Streptococcus pneumoniae* with reduced susceptibility to beta-lactam antimicrobial agents are an increasingly encountered problem in clinical practice. The incidence of infection with penicillin-resistant pneumococci now exceeds 30% in most areas of the United States (22). There have been reports of failure of conventional antimicrobial regimens in acute otitis media and meningitis caused by highly penicillin-resistant pneumococci (2, 3, 11, 19, 22). These therapeutic failures suggest that the current standards for predicting effective therapy of infection with these organisms may need to be altered.

Amoxicillin and amoxicillin-clavulanate are orally administered beta-lactams, with thrice daily dosing in humans commonly used to treat infections caused by *S. pneumoniae*. Although these agents have the lowest MICs for *S. pneumoniae* among currently available oral beta-lactams, the precise MIC breakpoint separating effective and noneffective in vivo activity is currently unknown. The use of animal models has become integral in the evaluation of the therapeutic efficacies of antimicrobial agents. Animal models can describe the time course of in vivo antibiotic therapy and dose-response relationships and determine the influence of antimicrobial agent resistance in vitro on various in vivo outcomes observed during the treatment of these infections (5, 10, 13, 24).

The goals of these studies were (i) to stimulate the human pharmacokinetic profiles of amoxicillin and amoxicillin-clavulanate in the murine infection model in order to appropriately compare these results to those that might be expected in humans and (ii) to characterize the in vivo activities of amoxicillin and amoxicillin-clavulanate against strains of *S. pneumoniae* for which penicillin and amoxicillin MICs vary. By observing efficacy against organisms with a range of in vitro activity, we hoped to identify in vivo MIC breakpoints of amoxicillin and amoxicillin-clavulanate for *S. pneumoniae*. These studies would also enable us to determine if clavulanate enhances the in vivo activity against strains of *S. pneumoniae* with various susceptibilities to penicillin.

(Part of this research was presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Calif., September 1995.)

**MATERIALS AND METHODS**

**Bacteria, media, and antibiotics.** *S. pneumoniae* ATCC 10813 and 49619 and 15 clinical isolates (provided by Fred Tenover of the Centers for Disease Control and Prevention and Gary Doern of the University of Iowa) were used for these experiments. Organisms were grown, subcultured, and quantified in Mueller-Hinton broth (MHB) (Difco Laboratories, Detroit, Mich.) and on sheep blood agar plates (Remel, Milwaukee, Wis.). Amoxicillin and amoxicillin-clavulanate were provided by SmithKline Beecham, Philadelphia, Pa.

**In vitro studies.** MICs of amoxicillin and penicillin for the various isolates were determined by standard National Committee for Clinical Laboratory Standards (NCCLS) microdilution methods with geometric two-fold serial dilutions in cation-adjusted MHB supplemented with 3% lysed horse erythrocytes. Each well contained 100 μl (50 μl of inoculum plus 50 μl of drug-containing MHB). The final inoculum was 1 × 10⁵ to 5 × 10⁶. MIC endpoints were determined by visual inspection after CO₂ incubation (Forma Scientific Incubator, Marietta, Ohio) at 37°C for 18 to 24 h. Final results were expressed as geometric means of two to four determinations.

**Mouse preparation and infection.** Six-week-old, specific-pathogen-free, female ICR/Swiss mice weighing 23 to 27 g (Harlan Sprague-Dawley, Madison, Wis.) were rendered neutropenic (neutrophils, <100/mm³) by injecting cyclophosphamide (Mead Johnson Pharmaceuticals, Evanville, Ind.) intraperitoneally 4 days (150 mg/kg of body weight) and 1 day (100 mg/kg) before experi-

---

* Corresponding author. Mailing address: Wm. S. Middleton Memorial VA Hospital, 2500 Overlook Terrace, Madison, WI 53705. Phone: (608) 262-7020. Fax: (608) 262-7685. E-mail: drandes@facstaff.wisc.edu.
mental infection. Previous studies have shown that this regimen produces neutropenia in this model for 5 days (6). Renal impairment was produced by one intraperitoneal injection of uranyl nitrate (10 mg/kg) 3 days before therapy with an antimicrobial agent. This intervention causes a reversible acute tubular necrosis and a subsequent significant stable reduction in renal function for at least 7 days (6, 14, and data not shown). Both cultures of freshly plated bacteria were grown to logarithmic phase overnight to an absorbance of 0.3 at 580 nm (Spectronic 20; Bausch and Lomb, Rochester, N.Y.). After a 1.10 dilution into fresh MHB, bacterial counts of the inoculum ranged from 10^6 to 10^9 CFU/ml. Thigh infections with each of the S. pneumoniae strains were produced by injection of 0.1 ml of inoculum into each of the ether-anesthetized mice 2 h before therapy with an antimicrobial agent was begun.

**Table 1. MICs of amoxicillin and penicillin G for strains of S. pneumoniae**

<table>
<thead>
<tr>
<th>Organism</th>
<th>Penicillin G (mg/liter)</th>
<th>Amoxicillin (mg/liter)</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>S. pneumoniae</em> ATCC 10813</td>
<td>0.016</td>
<td>0.008</td>
</tr>
<tr>
<td><em>S. pneumoniae</em> R20</td>
<td>0.031</td>
<td>0.125</td>
</tr>
<tr>
<td><em>S. pneumoniae</em> 135</td>
<td>0.062</td>
<td>0.125</td>
</tr>
<tr>
<td><em>S. pneumoniae</em> 131</td>
<td>0.062</td>
<td>0.25</td>
</tr>
<tr>
<td><em>S. pneumoniae</em> 1396</td>
<td>0.25</td>
<td>0.5</td>
</tr>
<tr>
<td><em>S. pneumoniae</em> 1199</td>
<td>0.25</td>
<td>1.0</td>
</tr>
<tr>
<td><em>S. pneumoniae</em> R3</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td><em>S. pneumoniae</em> 1325</td>
<td>0.5</td>
<td>2.0</td>
</tr>
<tr>
<td><em>S. pneumoniae</em> 1285</td>
<td>0.5</td>
<td>1.0</td>
</tr>
<tr>
<td><em>S. pneumoniae</em> 1020</td>
<td>2.0</td>
<td>2.0</td>
</tr>
<tr>
<td><em>S. pneumoniae</em> 1293</td>
<td>2.0</td>
<td>2.0</td>
</tr>
<tr>
<td><em>S. pneumoniae</em> 138</td>
<td>2.0</td>
<td>2.0</td>
</tr>
<tr>
<td><em>S. pneumoniae</em> 1329</td>
<td>4.0</td>
<td>2.0</td>
</tr>
<tr>
<td><em>S. pneumoniae</em> 146</td>
<td>4.0</td>
<td>4.0</td>
</tr>
<tr>
<td><em>S. pneumoniae</em> 145</td>
<td>4.0</td>
<td>4.0</td>
</tr>
<tr>
<td><em>S. pneumoniae</em> 673</td>
<td>5.6</td>
<td>8.0</td>
</tr>
</tbody>
</table>

**Pharmacokinetics.** Pharmacokinetic profiles for amoxicillin following doses of 7, 20, and 48 mg/kg resulted in peak/dose ratios of 0.7 ± 0.3 (mean ± standard deviation) and 1.5 ± 0.4 and elimination half-lives of 21 ± 3 and 65 ± 13 min in mice with normal and impaired renal function, respectively. The peak level was twofold higher in renally impaired mice compared to that in mice with normal renal function. The elimination half-life was increased 3.1-fold in the renally impaired mice, approximating that observed in humans with normal renal function. The serum concentrations following a subcutaneous dose of 7 mg of amoxicillin per kg in renally impaired mice and a 500-mg oral dose in normal human volunteers are shown in Fig. 1. Although both doses produced similar mean peak levels (12.0 mg/liter in mice and 10.9 mg/liter in humans), peak levels occurred much earlier in the murine model. Since the rates of elimination were very similar in mice and humans, the duration of time that drug levels in serum would exceed the MIC would be 1 to 1.5 h longer in humans than in the murine model.

**RESULTS**

**MIC determinations.** The MICs of amoxicillin and penicillin G for the 17 study strains are shown in Table 1. The MICs varied 500-fold for amoxicillin and 1,000-fold for penicillin. In general, AUCs for amoxicillin were similar or two- to fourfold lower than AUCs for penicillin G. Based on NCCLS breakpoints, the organisms studied included one strain susceptible to penicillin (MIC, 0.1 mg/liter), eight strains with intermediate susceptibility (MICs, 0.1 to 1.0 mg/liter), and eight strains resistant to penicillin (MICs, >2.0 mg/liter).
Organism growth in thighs. Organisms exhibited logarithmic growth prior to therapy in all control experiments. Bacterial numbers at the start of therapy ranged from 6.03 to 7.46 log_{10} CFU per thigh. Control growth over 24 h for each organism studied is shown in Fig. 2a. All organisms grew at 2.06 to 3.35 log_{10} CFU per thigh over 24 h in untreated control animals.

In vivo efficacy. Organization growth (positive numbers) or killing (negative numbers) following 24 h of therapy with amoxicillin (7 mg/kg) and amoxicillin-clavulanate (7/1.75 mg/kg) every 8 h is shown in Fig. 2b and c, respectively. Two of the most amoxicillin-susceptible strains were not studied with amoxicillin-clavulanate. The differences between the extent of killing for amoxicillin and amoxicillin-clavulanate at the end of 24 h of therapy were small and insignificant ($P = 0.06$ to 1.0). In fact, the two strains (138 and 1285) for which differences were closest to being significant ($P = 0.06$) gave better results with amoxicillin, not amoxicillin-clavulanate. The magnitude of killing ranged from 1.5 to 4.0 log_{10} CFU per thigh. The extent of organism killing with both drugs was dependent on the MICs for the organisms. Significant killing was observed with all organisms for which MICs were 2 mg/liter or less, while growth or minimal net change in bacterial numbers was observed with organisms for which MICs were 4 mg/liter or greater.

Mortality following 4 days of antimicrobial therapy with amoxicillin (7 mg/kg/8 h) and amoxicillin-clavulanate (7/1.75 mg/kg/8 h) is shown in Table 2. Mortality was 100% within 3 days in untreated controls for all strains. The MICs for the various study organisms were predictive of efficacy when mortality was used as an endpoint as well. All animals that were infected with organisms for which MICs were 1 mg/liter or less survived. With the two strains for which MICs were 2 mg/liter, 20 to 40% mortality was observed with amoxicillin, but no mortality was observed with amoxicillin-clavulanate. In contrast, mortality was 80 to 100% in mice infected with organisms for which MICs were 4 mg/liter or greater.

Correlation between in vivo efficacy and duration of time serum levels exceeds the MIC. As shown in Fig. 3, there was an excellent correlation between mortality after 4 days of therapy and the duration of time that serum levels exceeded the MIC for both amoxicillin and amoxicillin-clavulanate ($R^2 = 95\%$). The highest mortality rates, 80 to 100%, were seen when serum levels exceeded the MIC for less than 20% of the dosing interval. Maximal survival was approached when serum levels exceeded the MIC for 40% of the 8-h dosing interval, or approximately 3 h per dose.

The correlation between therapeutic efficacy, measured by killing or growth of bacteria at 24 h, and the duration of time that serum levels exceeded the MICs of amoxicillin and amoxicillin-clavulanate against the various organisms is shown in Fig.

![Graph showing correlation between in vivo efficacy and duration of time serum levels exceed the MIC](image-url)
amoxicillin-clavulanate at 7 mg/kg every 8 h. Each value represents the mean for two thighs. The graph also includes data from the study of additional dosage regimens. Organisms that were not killed at 7 mg/kg/8 h were killed at dosage regimens of 20 mg/kg/8 h. Organisms that were killed at 7 mg/kg/8 h exhibited growth when the dose was reduced to 2.0 or 0.5 mg/kg/8 h. An excellent correlation between in vivo antimicrobial activity and time above MIC was obtained ($R^2 = 80\%$). A static effect or no net growth was demonstrated when the time above MIC was 20 to 30% of the dosing interval. Maximum in vivo killing was observed with time above MICs of 50 to 60% of the 8-h dosing interval.

**DISCUSSION**

Escalating resistance to antimicrobial agents seen in clinical isolates of *S. pneumoniae* has reduced the efficacy of many oral drugs used to treat respiratory infections such as otitis media (2–4). Assessing the utility of different antimicrobial agents and respective dosing regimens against resistant pneumococci has thus become a pressing priority. The use of animal models to predict effective dosing regimens in humans is one approach to this problem (5, 7). Despite the many positive aspects of animal models, several criticisms, such as altered pharmacokinetics in animals, have precluded direct application of results to clinical practice in humans. By altering the renal kinetics of amoxicillin in the murine thigh infection model, we have simulated the serum concentration time course of this agent observed in humans. Doses of 7 mg/kg produced a kinetic elimination profile similar to that seen with a 500-mg oral dose in humans with normal renal function. However, subcutaneous absorption of amoxicillin in mice was faster than gastrointestinal absorption of the drug in humans. This resulted in similar peak concentrations but a shorter time above MIC in the mice than would be observed in humans.

Prior experiments in a murine infection model have shown that the in vivo efficacies of antimicrobial agents correlate closely with their respective in vitro activities (6, 20, 24). Several clinical studies have demonstrated a similar relationship between MICs and in vivo outcomes (1, 17). In our infection experiments, the in vivo efficacies of amoxicillin and amoxicillin-clavulanate were inversely related to the MICs for the infecting organisms over a wide range of susceptibilities, including penicillin-resistant organisms. At a dose of 7 mg/kg, bacterial killing was observed for organisms for which MICs were as high as 2 mg/liter. A recent clinical trial of augmentin in acute otitis media demonstrated equal efficacies in patients infected with penicillin-susceptible, -intermediate and resistant strains of *S. pneumoniae* (15). The highest MIC of amoxicillin observed in this study was 2 mg/liter.

Several experimental models have proven that therapeutic efficacy for the beta-lactam class of antibiotics correlates best with the duration of time that serum levels exceed the MIC for the infecting organism (8, 9, 12). With the penicillins, bacteriostatic efficacy has been achieved in the thigh infection studies when the magnitude of this parameter reaches 25 to 30%, while maximal bacteriologic efficacy and survival are predictably seen when serum levels remain above the MIC for 40 to 50% of the dosing interval (8). We found that the percentage of time above the MIC required for utility of amoxicillin and amoxicillin-clavulanate did not differ for penicillin-susceptible and -resistant strains of *S. pneumoniae*. Again, bacteriologic efficacy and survival were maximal when serum levels exceeded the MIC for 40 to 50% of the 8-h dosing interval.

**Determination of MIC breakpoints of amoxicillin and amoxicillin-clavulanate in humans can be estimated by calculating the highest drug concentration that is maintained in serum for at least 50% of the dosing interval with standard oral doses. Following a 250- and a 500-mg dose of amoxicillin in normal volunteers, serum levels exceed 1.0 and 2.0 mg/liter, respectively, for at least 50% of the dosing interval. NCCLS-approved MIC breakpoints for these agents are currently 0.5 mg/liter for susceptible, 1.0 mg/liter for intermediate, and 2.0 mg/liter for resistant strains. Based on the simulation of human pharmacokinetics in this animal model, estimated breakpoints of amoxicillin and amoxicillin-clavulanate for *S. pneumoniae* would be 1 dilution higher, at 1.0 mg/liter for susceptible, 2.0 mg/liter for intermediate, and 4.0 mg/liter for resistant strains. If the recently suggested dosage escalation to 875 mg twice daily is considered, serum levels would remain above a MIC of 1 mg/liter for an adequate percentage of the 12-h dosing interval, making the above-mentioned breakpoints acceptable for this regimen as well. Our results, even in the presence of profound neutropenia and the high clinical success with amoxicillin-clavulanate against strains of *S. pneumoniae* for which...
amoxicillin MICs are as high as 2 mg/liter, support a reevaluation of current breakpoints.

ACKNOWLEDGMENTS

We thank Fred Tenover of the CDC and Gary Doern of the University of Iowa for providing the clinical isolates used in these experiments. This work was supported by a grant from SmithKline Beecham, Philadelphia, Pa.

REFERENCES